Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Osteoporos Int. 2017 Jan 16;28(3):767–774. doi: 10.1007/s00198-017-3906-6

Figure 1.

Figure 1

1 Change from baseline after three months of treatment with the three tested bisphosphonates (Ibandronate, Alendronate and Risedronate) in CTX (upper panel) and PINP (lower panel). Shadowed zone indicates change > least significant change for the marker

Ibn= Ibandronate; Aln = Alendronate; Ris = Risedronate